Inactief instrument

Andere talen RXi Pharmaceuticals Corp Nasdaq

Aandelen

US74979C3034

slotkoers Nasdaq Andere beurzen
- ^USD	-

09/05	Phio Pharmaceuticals Corp. Rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
22/04	Phio Pharmaceuticals Corp. presenteert nieuwe gegevens over haar belangrijkste klinische productkandidaat, PH-762	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update	09/05
Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)	30/04
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells	22/04
Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762	22/04
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)	16/04
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology	16/04
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)	11/04
National Spotlight Features Phio’s Innovative RNAi Technology Platform	03/04
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update	02/04
North American Morning Briefing : Stocks Seen -2-	02/04
Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03
Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	21/03
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research	13/03
Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research	13/03
Phio Pharmaceuticals Secures Patent for Compounds Treating Age Related Skin Disorders	06/03
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03
Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders	06/03
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies	31/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RXi Pharmaceuticals Corp Nasdaq

Aandelen

US74979C3034

Andere talen

Filters